BTIG Reiterates a Buy Rating on Viking Therapeutics (VKTX) With a $125 PT

Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the best strong buy stocks to invest in according to Wall Street. On September 22, BTIG analyst Justin Zelin reiterated a Buy rating on Viking Therapeutics, Inc. (NASDAQ:VKTX) and set a $125.00 price target.

Viking Therapeutics (VKTX) Soars 9.7% on Looming Weight Loss Drug Trial Results

The analyst based the optimistic rating on the company’s strong position in the obesity and metabolic disease market, reasoning that the recent acquisitions conducted by the large pharmaceutical companies, including the acquisition of Metsera by Pfizer, highlight the strategic significance and high valuation of the companies in the sector.

According to Zelin, Viking Therapeutics, Inc. (NASDAQ:VKTX) is considered one of the few remaining independent industry players that boast an advanced and mature portfolio, factors that make the company an attractive target for acquisitions or partnerships.

Viking Therapeutics, Inc. (NASDAQ:VKTX) is a clinical-stage company that develops therapies for metabolic and endocrine disorders.

While we acknowledge the potential of XXXX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than XXXX and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.